Health Catalyst (NASDAQ:HCAT) Price Target Raised to $9.00 at Stephens

Health Catalyst (NASDAQ:HCAT) had its target price upped by Stephens from $7.00 to $9.00 in a report released on Thursday morning,Benzinga reports. Stephens currently has an equal weight rating on the stock.

A number of other research analysts also recently weighed in on the stock. Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Piper Sandler reduced their target price on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Royal Bank of Canada increased their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.71.

Health Catalyst Stock Down 9.5 %

NASDAQ:HCAT traded down $0.80 on Thursday, hitting $7.65. The stock had a trading volume of 637,468 shares, compared to its average volume of 562,503. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market cap of $465.50 million, a P/E ratio of -6.08 and a beta of 1.32. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The firm’s fifty day simple moving average is $8.15 and its two-hundred day simple moving average is $7.21.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.22) EPS. Analysts predict that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. This trade represents a 5.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock valued at $257,555 in the last three months. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently modified their holdings of HCAT. Inspire Investing LLC purchased a new position in shares of Health Catalyst in the first quarter valued at about $355,000. Acadian Asset Management LLC boosted its stake in shares of Health Catalyst by 38.3% during the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after purchasing an additional 200,494 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of Health Catalyst during the 1st quarter valued at about $98,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Health Catalyst by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after purchasing an additional 2,831 shares in the last quarter. Finally, Kennedy Capital Management LLC bought a new stake in shares of Health Catalyst during the 1st quarter valued at about $8,780,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.